University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
GOG 3001/ Amgen TRINOVA-3
Official Title

GOG 3001/ Amgen TRINOVA-3 - A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

Description

Participants in this study are women with advanced epithelial ovarian, primary peritoneal, or fallopian tube cancers who are receiving initial treatment. The purpose of this study is to see if participants who are treated with paclitaxel and carboplatin (chemotherapy drugs) plus AMG 386, followed by 18 months of AMG 386 continued after the chemotherapy, will have an improved outcome compared to participants treated with paclitaxel and carboplatin plus AMG 386 placebo, followed by 18 months of AMG 386 placebo after the chemotherapy.

Approximately 2000 women are expected to participate in this study at up to 300 sites around the world. Approximately 10 subjects from the University of Iowa may participate in the study.

Start Date
September 27, 2013
End Date
November 1, 2018
Gender Preference
Female
Age Group
18 - 99 years
Principal Investigator
David Bender, MD
Contact Info

Sharon Stockman, (319) 356-2015

Department
Obstetrics/ Gynecology
Keywords
201209506 ; Bender ; cancer ; epithelial ovarian cancer ; fallopian tube cancer ; Phase three ; primary peritoneal cancer ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.